StocktoriaPMGC Holdings Inc. ELAB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | $590,084 | — | $1.7M | $766,277 |
| Gross profit | $185,314 | — | $1.1M | $447,309 |
| Net income | -$7.7M | -$6.2M | -$4.3M | -$1.8M |
| Operating cash flow | -$5.9M | -$5.5M | -$4.6M | -$1.6M |
| Free cash flow | -$6.4M | -$5.5M | -$4.6M | — |
| Total assets | $12.9M | $9.0M | $5.2M | $1.9M |
| Total liabilities | $5.0M | $2.3M | $1.4M | $760,873 |
| Shareholders' equity | $7.8M | $6.7M | $3.8M | $1.1M |
| Ratios | ||||
| Gross margin | 31.4% | — | 66.2% | 58.4% |
| Net margin | -1313.0% | — | -251.2% | -234.9% |
| FCF margin | -1080.5% | — | -266.7% | — |
| Return on assets | -60.2% | -69.4% | -82.9% | -95.1% |
| Return on equity | -98.9% | -93.8% | -112.4% | -159.1% |
| Current ratio | 1.74 | 3.36 | 3.79 | 2.64 |
| Revenue growth | — | — | 123.5% | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001840563 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.